About Us>Our team > Reshma L. Mahtani DO

Reshma L. Mahtani DO

Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida

Highlights

  • Board member since 2023
  • Medical Advisory Board member
  • Medical oncologist and clinical researcher focusing on new therapies for breast cancer
  • Editor-in-chief of Practice Updates, an online educational platform for physicians
featured_paragraph

Reshma L. Mahtani, DO, is a medical oncologist practicing in South Florida. She is the chief of breast medical oncology at Miami Cancer Institute at Baptist Health South Florida, which is a member of the Memorial Sloan Kettering Alliance.

general_content

Dr. Mahtani is committed to medical education. She speaks nationally and internationally and has served as program chair for several officially licensed Best of ASCO programs for the American Society of Clinical Oncology. She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer.

Her current role is chief of breast medical oncology at Miami Cancer Institute. Previously she served as co-leader of the breast cancer program at the University of Miami at Sylvester Comprehensive Cancer Center, where she oversaw the clinical trial program across the network. She previously served on the ASCO Quality Oncology Practice Initiative Steering Committee and is currently editor-in-chief of Practice Updates, an online educational platform for physicians.

She is honored to join LBBC’s Board of Directors. She is committed to medical education and has been involved in educating both providers and patients. Keenly aware of the key role that education plays in improving patient outcomes, she has been involved in several initiatives that have helped patients make informed decisions about their health. 

contributions_carousel

Contributions

Tamoxifen

08/05/23 | BY: Reshma L. Mahtani

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More
 | 11 Min. Read |

Hormone receptor-positive

05/23/23 | BY: Reshma L. Mahtani

Hormone receptor-positive, or HR-positive, breast cancer grows in response to the hormones estrogen and progesterone. These hormones occur naturally in the body and prompt cell action in different ways.

Read More
 | 15 Min. Read |

Circulating tumor DNA

03/30/23 | BY: Sameer Gupta, Reshma L. Mahtani

Circulating tumor DNA, or ctDNA, tests analyze a blood sample to look for fragments of genetic information (DNA) shed by cancer cells into the bloodstream. Another term used for this testing is liquid biopsy.

Read More
 | 12 Min. Read |

Triple-negative

05/05/22 | BY: Reshma L. Mahtani

While some breast cancers express hormone receptors or have too many copies of the HER2 gene, other breast cancers may not have these characteristics. Triple-negative breast cancers (TNBC) do not express estrogen receptors, progesterone receptors, or HER2 receptors. About 10% to 15% of breast cancers are triple-negative.

Read More
 | 13 Min. Read |

HER2-positive

05/05/22 | BY: Reshma L. Mahtani

If you are diagnosed with HER2-positive breast cancer, you may be wondering what that means. Read about the ins-and-outs of HER2-positive breast cancer.

Read More
 | 14 Min. Read |

Breast cancer treatment during the coronavirus outbreak

04/01/20 | BY: Eric Fitzsimmons

Drs. Julie Gralow and Reshma Mahtani explain how people in treatment for breast cancer can balance the known threat of breast cancer against what was known about the potential threat of developing COVID-19 in the first few months of the pandemic.

Read More
 | 8 Min. Read